Meyka Pro banner
Immuron Limited

Immuron Limited (IMRN) Stock Overview

Explore Immuron Limited’s financial performance, market position, analyst ratings, and future outlook.

IMRNNASDAQ
HealthcareBiotechnology
$1.80
$0.69(62.16%)
U.S. Market opens in 10h 16m

Immuron Limited (IMRN)

Meyka AI Score

Z

Key Financials

Market Cap11.3M
P/E Ratio-2.01
EPS (TTM)$-0.21
ROE-0.79%
Fundamental Analysis

AI Price Forecasts

1 Month$1.26
3 Months$0.64
1 Year Target$0.22

IMRN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Immuron Limited (NASDAQ: IMRN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Immuron Limited's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of IMRN on the NASDAQ shows an RSI of 76.98, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $0.22 for the NASDAQ listing.

Key metrics behind Immuron Limited's NASDAQ-traded stock include a P/E ratio of -2.01 and a market capitalization of 11.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of IMRN on the NASDAQ.

Price Performance (NASDAQ: IMRN)

1-Day Change
62.16%
5-Day Change
56.52%
1-Month Change
66.67%
3-Month Change
41.73%
6-Month Change
141.20%
Year-to-Date (YTD) Change
136.07%
1-Year Change
-4.76%
3-Year Change
-10.00%
5-Year Change
-62.89%
All-Time (Max) Change
-78.47%

Contact Information

61 3 9824 5254
62 Lygon Street, Carlton, VIC, 3053

Company Facts

70 Employees
IPO DateJun 9, 2017
CountryAU
Actively Trading

Frequently Asked Questions